271 results about "Kidney disorder" patented technology

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

By constructing a mouse model of the specific knockout TILRR, it is found that the specific knockout TILRR remarkably slows down the kidney inflammation signal flow of an object, inhibits kidney diseases of the object and reduces the kidney fibrosis degree and / or inflammatory response of the object. Thus, the present invention relates to the use of TILRR as a target in the prevention and / or treatment of kidney disease. Specifically, the invention provides application of the following reagents in preparation of drugs for slowing down kidney inflammation signal flow of an object, inhibiting kidney diseases of the object and reducing kidney fibrosis degree and / or inflammatory response of the object: (1) a reagent for reducing expression of TILRR protein of the object; and / or (2) an agent that reduces the activity of a TILRR protein expressed by a subject.

Methods are disclosed for delivering a composition comprising an adeno-associated virus (AAV) to one or more kidney cell types in a subject with or without immunity against AAV, including locally delivering to the kidney of the subject an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein via renal pelvic injection, wherein the renal pelvic injection comprises direct renal pelvic injection or retrograde transureteral renal pelvic injection. Methods are also disclosed for treating a kidney disorder in a subject with or without immunity against AAV, comprising locally delivering to the kidney of the subject via renal pelvic injection, including direct renal pelvic injection and retrograde transureteral renal pelvic injection, an adeno-associated virus (AAV) comprising a genome and an AAV capsid protein, wherein the genome encodes a therapeutic agent that treats the kidney disorder in the subject. The AAV can be AAVKP1, AAVKP2, AAVKP3, AAVDJ, AAV2G9, AAV2.7m8, AAV3, AAVLK03, or AAVShH10.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Disclosed are methods and uses for treating a subject having a condition selected from liver disease, Cushing's syndrome or Cushing's disease, cancer, infection, inflammation, cardiovascular, endocrine or kidney disease, and combinations thereof, or other disease that may thus be administered a drug that may cause hepatotoxicity, the methods and uses having no adverse effects on the liver. The liver diseases comprise fatty liver diseases, high-level liver enzyme can be effectively reduced, and good safety is achieved. The methods and uses include administering to a subject an effective amount of a selective non-steroidal glucocorticoid receptor modulator, such as relacan, including methods and uses for use in combination with other drugs, without adversely affecting liver enzyme levels or liver function. In embodiments, another drug may be a drug that may cause hepatotoxicity, such as a drug that inhibits the CYP3A enzyme, such as itraconazole or ketoconazole.

The invention relates to a flavonoid active fraction of an Abelmoschi corolla, a preparation method and an application thereof, and belongs to the field of traditional Chinese pharmaceutics. A high-purity Abelmoschi corolla flavonoid active fraction is prepared, which is found to have better therapeutic activity for kidney disease, and especially have a significant therapeutic effect for diabetic kidney disease and lupus nephritis, or contrast-induced kidney injury and eye diseases. Meanwhile, the Abelmoschi corolla flavonoid active fraction described in the invention also has good safety.

The embodiment of the invention discloses a model optimization method based on transfer learning. The method comprises the following steps: acquiring to-be-migrated learning data, wherein the to-be-migrated learning data comprises source domain data associated with pathological characteristics of kidney diseases; semantic alignment processing is carried out on the source domain data and target domain data, the target domain data is kidney disease pathology data, and a semantic alignment result is obtained; determining a feature distribution result corresponding to the target domain data, and determining a migration weight corresponding to the source domain data based on the feature distribution result and the semantic alignment result; and optimizing the target domain model based on the migration weight, the source domain data and the target domain data to obtain an optimized target domain model. According to the embodiment of the invention, the accuracy and robustness of the target domain model in a kidney disease pathological diagnosis task and the generalization ability of different data distributions can be remarkably improved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing into a kidney disease by administering an angiopoietin-like 3 (ANGPTL3) inhibitor and a solute carrier family 5 member 2 (SLC5A2) inhibitor, and methods of identifying a subject having an increased risk of developing into a kidney disease.

The invention relates to the technical field of gene engineering, in particular to a method for constructing a pou3f3 mutant model, the pou3f3 mutant model and application. The method comprises the following steps: designing an sgRNA target nucleotide sequence of a targeted pou3f3 gene, shearing the pou3f3 gene in an animal model through a CRISPR / Cas9 gene editing technology so as to realize pou3f3 gene mutation, and finally carrying out passage screening to obtain a double homozygous mutant of pou3f3a mutation and pou3f3b mutation, a pou3f3a homozygous mutant or a pou3f3b homozygous mutant model. According to the method, synchronous knockout of the two homologous genes pou3f3a and pou3f3b can be effectively realized, a reliable experimental model is provided for researching gene functions and related diseases, and the model can also be used for researching hereditary kidney diseases.

The invention relates to the field of medical treatment, in particular to application, a model and a method of a protein fragment of urine regulatory protein in preparation of a kidney disease early detection product, and the amino acid sequence of the protein fragment of the urine regulatory protein is any shown in SEQ ID NO.1-8. The model constructed according to the protein fragment of the urine regulatory protein can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and by analyzing the unique mode of the protein fragment existing in a urine sample, the model which indicates renal insufficiency, renal function and renal function can be identified before the traditional clinical biomarker is abnormal. Therefore, intervention can be carried out earlier.

The invention discloses a preparation method of a myeloid cell triggered receptor 2 protein polyclonal antibody and application of the polyclonal antibody in inhibition of renal fibrosis, and belongs to the technical field of medical molecular biology. The myeloid cell triggered receptor 2 protein is expressed by macrophages, and verification in the mechanism aspect is carried out on the protein; meanwhile, the polyclonal antibody is synthesized according to the polypeptide of the protein, then the effect of the antibody on treating the renal fibrosis is verified again, and a more targeted and personalized method is provided for diagnosis, treatment and management of the renal fibrosis and related kidney diseases.

The invention relates to the technical field of preparation of organoids, and discloses a method for regulating and controlling human induced pluripotent stem cells to differentiate into kidney organoids, which comprises the following steps: resuspending a cell cluster formed by human induced pluripotent stem cells by using a basic differentiation culture solution containing a GSK-3beta inhibitor, inoculating the cell cluster into an ultralow adsorption cell culture plate, and starting to culture, marking the time as the 0th hour of differentiation; and after culturing for 70-76 hours, replacing the basic differentiation culture solution containing the GSK-3beta inhibitor with a basic differentiation culture solution containing a Knockout TM serum substitute (KSR), and continuing to carry out differentiation culture. By adopting the method disclosed by the invention, the human induced pluripotent stem cells can be efficiently, quickly, simply, conveniently and stably subjected to directional induced differentiation into kidney organs containing podocytes, renal tubules and other structures, and the time for constructing a kidney in-vitro model can be shortened, so that the research on kidney diseases, kidney development and the like can be greatly assisted; and a powerful platform is provided for kidney toxicity assessment.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat Cys-C protein and application. The monoclonal antibody combination provided by the invention comprises monoclonal antibodies 4D5 and 3F3, and amino acid sequences of complementary determining regions (CDR) of variable regions of a heavy chain and a light chain of the monoclonal antibodies 4D5 and 3F3 are respectively shown as SEQ ID NO.1 to SEQ ID NO.12. The antibody combination has high specificity and sensitivity, and can effectively recognize cat Cys-C recombinant protein and natural cat Cys-C protein. According to the double-antibody sandwich ELISA detection method constructed based on the antibody combination, positive signals can still be generated under the low concentration of 1ng / mL, no obvious cross reaction exists, and the detection accuracy is remarkably improved. The antibody combination can be used for preparing a detection kit, a test strip, an antibody chip and other tools, and is suitable for cat kidney function evaluation and early auxiliary diagnosis of kidney diseases.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses application of SAA1 as a target spot in preparation of a medicine for preventing and treating kidney diseases, and belongs to the field of gene functions, application and biological medicine. In-vivo and in-vitro experiments prove that in an ischemia / reperfusion or ureteral obstruction induced mouse kidney disease model, the knockout of the SAA1 gene can relieve renal interstitial vascular endothelial cell injury, recover a renal capillary network, improve vascular permeability, reduce collagen deposition, inhibit renal fibrosis and effectively delay the progress of kidney diseases; furthermore, by adopting the SAA1 recombinant protein vaccine to immunize mice, the organism can be induced to generate a protective neutralizing antibody, and the SAA1 recombinant protein vaccine has a remarkable protective effect on kidney diseases induced by ischemia / reperfusion and ureteral obstruction. Therefore, the SAA1 is an intervention target for preventing and treating the kidney diseases, the SAA1 recombinant protein vaccine is an effective means for preventing and treating the kidney diseases, and active immunization by adopting the vaccine is an effective strategy for preventing and treating the kidney diseases.

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

The present invention provides stem cells enriched with healthy functional mitochondria, pharmaceutical compositions comprising these cells and methods of use thereof for treating renal diseases, disorders and symptoms thereof where the disease may or may not be associated with acquired mitochondrial dysfunction.

To simply provide information showing a degree of a kidney disease of a feline animal.SOLUTION: A urine inspection system includes a storage part and a control part. The storage part stores kidney disease information on a relation between a level of a D-amino acid in urine of a feline animal and a degree of a kidney disease of the feline animal. The control part receives D-amino acid information showing the level of the D-amino acid in the urine from the feline animal from a user terminal belonging to an owner or an inspection institute of the feline animal. Then, the control part estimates the degree of the kidney disease of the feline animal on the basis of the received D-amino acid information and the kidney disease information and transmits kidney disease degree information showing the estimated degree of the kidney disease to the user terminal.SELECTED DRAWING: Figure 4

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The invention belongs to the technical field of kidney disease detection, and particularly relates to a renal function dry-type biochemical detection chip and a use method thereof. The chip is combined with a dry biochemical reaction layer through a micro-fluidic technology, and can be used for synchronously detecting renal function markers such as urine creatinine, urea nitrogen and cystatin C. The chip adopts a multi-layer modular lamination design, and sequentially comprises a bottom plate, an electrode layer, a detection layer, a binding layer and a sample adding layer from bottom to top, and each layer is made of a high-molecular polymer with excellent biocompatibility, so that the detection process is not interfered, and the result is accurate and reliable. Sample flow is accurately controlled through the microfluidic channel, multi-index parallel detection is realized, and the detection efficiency is improved. A micro sensor is arranged in the chip, the reaction process is monitored in real time, and data accuracy is ensured. The system has the characteristics of portability and quick response, is suitable for clinical and family self-test, and provides a convenient and efficient solution for renal function monitoring.

In an illustrative embodiment, systems and methods for treating kidney disease in a human patient are disclosed. A method includes advancing a collapsible array of RF electrodes through a urinary tract of the patient in collapsed form and into a position in or near a renal pelvis. The effector is deployed to an expanded form to engage at least a portion of an interior wall of the renal pelvis. RF energy delivered through the array of electrodes target afferent nerves proximate the interior wall of the renal pelvis to inhibit or destroy their function. eGFR of the patient can be raised after treatment according to the method.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention relates to the technical field of medicines, discloses an application of 18 beta-glycyrrhetinic acid in a TMAO inhibitor, and further discloses an application of 18 beta-glycyrrhetinic acid in preparation of medicines for treating chronic diseases such as chronic kidney disease (CKD) and the like. The invention provides 18 beta-glycyrrhetinic acid (18 beta-GA) which is a substance capable of effectively inhibiting choline in intestinal tracts from being metabolized into TMAO for the first time, and the 18 beta-GA is efficiently combined with CutC / D and FMO to inhibit the generation of TMAO, so that the aggravating effect of TMAO on chronic kidney diseases is relieved; the invention further provides a method for improving kidney diseases through a CXCL12 / CXCR4 signal axis after the TMAO is reduced by the 18 beta-glycyrrhetinic acid, a new thought and a new method are provided for developing medicines for treating the TMAO related diseases, and a new way is expected to be developed for treating the chronic kidney diseases.

Disclosed are methods to treat a renal disorder in a mammal in need thereof by administering to the mammal in need of treatment an effective amount of a store operated calcium entry (SOCE) inhibitor or a pharmaceutically acceptable salt thereof.

The invention discloses application of Htr2b and an inhibitor thereof in prevention or treatment of chronic kidney diseases, provides application of Htr2b as a drug target in screening of drugs for prevention or treatment of chronic kidney diseases, and further provides application of the inhibitor of Htr2b in preparation of drugs for prevention or treatment of chronic kidney diseases. It is found that after the Htr2b function of DIO mice is inhibited, kidney injury caused by high fat is obviously relieved, the Htr2b inhibitor can inhibit important inflammatory factors MCP-1, IL-1, IL-6 and TNF-alpha and ectopic lipid deposition of the chronic kidney diseases, renal function markers of creatinine, urea nitrogen and UACR of the DIO mice can be obviously reduced, and the Htr2b inhibitor has the obvious effect of preventing or treating the chronic kidney diseases and has a good application prospect. The compound can be used for preparing medicines for preventing or treating chronic kidney diseases.

Use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or an isotopically labeled compound thereof in the preparation of a drug for preventing or treating neurodegenerative diseases, autoimmune and systemic inflammatory diseases, metabolic and cardiovascular diseases, respiratory diseases, ophthalmic diseases, or kidney diseases.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.